MIME-Version: 1.0
Server: WebSTAR/2.1 ID/32304
Message-ID: <b0b80f5a.3984@www.epixmed.com>
Date: Sat, 13 Dec 1997 21:38:38 GMT
Last-Modified: Tue, 01 Jul 1997 00:21:00 GMT
Content-type: text/html
Content-length: 3450

<HTML><HEAD>   <TITLE>Technology R&amp;D</TITLE></HEAD><BODY BGCOLOR="#FFFFFF"><P><CENTER><A NAME="top"></A><IMG SRC="graphics/logo_spacer.gif"WIDTH=113 HEIGHT=50 ALIGN=bottom><IMG SRC="graphics/techbanr.gif"WIDTH=320 HEIGHT=50 ALIGN=bottom><BR><A HREF="index.html"><IMG SRC="graphics/hometabs.gif" ALT="Home"WIDTH=67 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="index2.html"><IMGSRC="graphics/aboutabs.gif" ALT="About EPIX" WIDTH=99 HEIGHT=21BORDER=0 ALIGN=bottom></A><A HREF="ms325.html"><IMGSRC="graphics/m325tabs.gif" ALT="MS-325" WIDTH=76 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="technology.html"><IMGSRC="graphics/techtabs.gif" ALT="Technology R&amp;D" WIDTH=137HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="http://www.prnewswire.com/prn/owa/cn_liststory?id=120427"><IMGSRC="graphics/newstabs.gif" ALT="News" WIDTH=54 HEIGHT=21 BORDER=0ALIGN=bottom></A><BR><A HREF="publications.html"><IMG SRC="graphics/paprtabs.gif"ALT="Publications" WIDTH=109 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="employment.html"><IMGSRC="graphics/jobstabs.gif" ALT="Employment Opportunities" WIDTH=107HEIGHT=21 BORDER=0 ALIGN=bottom></A><A HREF="investor.html"><IMGSRC="graphics/invetabs.gif" ALT="Investor Info" WIDTH=106 HEIGHT=21BORDER=0 ALIGN=bottom></A><A HREF="request.html"><IMGSRC="graphics/datatabs.gif" ALT="Request Information" WIDTH=111HEIGHT=21 BORDER=0 ALIGN=bottom></A></CENTER><H1><HR><A NAME="proprietary"></A>Proprietary Technology</H1><P>The products under development by EPIX are based upon itsproprietary biophysics technology platform. The Company's productcandidates are small molecule chelates (soluble metal-organiccomplexes) containing a magnetically active metal element whichelicit a strong MRI signal and are designed to be safely excretedthrough the kidneys over time. EPIX has developed significantexpertise in the design, synthesis and characterization ofmetal-containing complexes for in vivo use. Compared to non-targetedcontrast agents used in MRI today, EPIX believes that its proprietarytechnology platform will enable it to design contrast agents capableof targeting specific tissues or organs by binding to particularproteins. The EPIX biophysics technology platform consists of two keyelements: Receptor-Induced Magnetic Enhancement (RIME), and EnzymeSensing Technology.<P><CENTER><TABLE BORDER=0>   <TR>      <TD>         <P><CENTER><IMG SRC="images/dots2-20big.gif" WIDTH=280         HEIGHT=145 ALIGN=bottom></CENTER>      </TD><TD>         <P><CENTER><IMG SRC="images/dock2-15_25.gif" WIDTH=226         HEIGHT=144 ALIGN=bottom></CENTER>      </TD></TR>   <TR>      <TD>         <P><CENTER><B>Chemical Structure of MS-325</B></CENTER>      </TD><TD>         <P><CENTER><B>MS-325 fitting into albumin binding site</B>         </CENTER>      </TD></TR></TABLE></CENTER><H1><HR>FAQ's/Topics</H1><BLOCKQUOTE><P><A HREF="t1RIME.html">What is Receptor-InducedMagnetic Enhancement?</A><P><A HREF="t2enzyme.html">What is Enzyme Sensing Technology?</A><P><A HREF="t3MS325.html">MS-325 Development Program</A><P><A HREF="t4R%26D.html">EPIX R&amp;D Programs</A></BLOCKQUOTE><P><CENTER><HR>&copy; 1997, EPIX Medical, Inc.<BR><P><CENTER>E-mail us at<A HREF="mailto:info@epixmed.com">info@epixmed.com</A></CENTER><P><CENTER>&nbsp;</CENTER></BODY></HTML>